The Women’s Health Initiative (WHI) study, published in 2002, is the most influential — and most misunderstood — study in the history of hormone replacement therapy. Its initial results, which were widely reported as showing that HRT causes breast cancer and heart disease, led to millions of women abruptly stopping treatment and a generation of providers becoming afraid to prescribe it.
The human cost of this overreaction has been enormous. Women suffered through severe menopause symptoms unnecessarily. Rates of osteoporotic fractures increased. The gap between what the evidence actually shows and what many women (and some providers) believe about HRT remains one of the biggest failures of medical communication in modern history.
This article provides a clear, evidence-based assessment of what we actually know about HRT safety in 2026.
The WHI studied two specific regimens: oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) in women with a uterus, and Premarin alone in women who’d had a hysterectomy.
The estrogen-only arm actually showed a decreased risk of breast cancer and no increased cardiovascular risk. It was stopped early simply because it was part of the same administrative trial as the combination arm.
The combination arm showed a small increased risk of breast cancer (8 additional cases per 10,000 women per year) and a small increased risk of cardiovascular events. However, these risks were concentrated in women who started HRT more than 10 years after menopause and were over age 60 — a population very different from the typical woman who begins HRT in her early 50s.
Critically, the WHI used oral conjugated equine estrogens (derived from horse urine, containing multiple estrogen compounds) and a synthetic progestin (medroxyprogesterone acetate) — not the bioidentical estradiol and micronized progesterone that modern HRT typically uses. Subsequent research has shown that bioidentical formulations and transdermal delivery have substantially different risk profiles.
Breast cancer risk with modern HRT is more nuanced than headlines suggest. Estrogen-only therapy does not increase breast cancer risk and may reduce it. The combination of estrogen plus micronized progesterone (the bioidentical progestogen) appears to carry less breast cancer risk than the synthetic progestins used in the WHI. When risk does exist, it’s small in absolute terms and similar to risks associated with common lifestyle factors like alcohol consumption, obesity, and sedentary behavior.
Cardiovascular risk depends heavily on timing. The “timing hypothesis” is now well-established: women who start HRT within 10 years of menopause or before age 60 show neutral or even beneficial cardiovascular effects. Women who start HRT later may face increased risk. This window of opportunity is a key consideration in Luvo’s prescribing approach.
Venous thromboembolism (blood clot) risk is increased with oral estrogen but not with transdermal estrogen. This is one of the most clinically actionable findings in modern HRT research — and it’s why Luvo offers transdermal options (cream and patches) alongside tablets.
Stroke risk shows a similar pattern to clotting risk: modestly increased with oral estrogen, not increased with transdermal delivery, and dose-dependent. Using the lowest effective dose and transdermal delivery minimizes this concern.
Luvo’s hormone replacement program is designed with risk minimization built into every level.
Formulation selection matters. Luvo uses bioidentical estradiol, not conjugated equine estrogens. The availability of transdermal options (cream and patches) allows women with clotting risk factors to avoid oral estrogen entirely.
Route-of-delivery matching means your provider recommends the delivery method based on your risk profile, not just convenience. Women with elevated thrombotic risk are guided toward transdermal options. Women with predominantly vaginal symptoms may use localized therapy with minimal systemic exposure.
Non-hormonal alternatives ensure that women who cannot safely use estrogen still have effective treatment options. Paroxetine and Desvenlafaxine provide meaningful relief without any hormonal exposure.
Timing considerations are respected. Luvo’s providers follow the evidence-based window of opportunity, recommending HRT initiation for appropriate candidates within 10 years of menopause onset.
Ongoing monitoring through regular follow-ups ensures that treatment remains appropriate and effective over time, with dose adjustments as needed.
This comprehensive, evidence-informed approach to risk management is what distinguishes Luvo from competitors that offer a limited menu of options with minimal clinical nuance. Explore the full hormone replacement program.
Estradiol is the gold standard for hormone replacement — but how it’s delivered to your body is just as important as the hormone itself. Different delivery methods produce different blood-level patterns, carry different risk profiles, target different tissues, and fit different lifestyles.
Luvo’s hormone replacement program offers five distinct estradiol formulations — more than most competitors provide. This comprehensive comparison helps you understand how each works, what it’s best for, and how they can be combined for complete symptom management.
Three of Luvo’s estradiol options provide systemic delivery — meaning the estradiol enters your bloodstream and circulates throughout your body, reaching estrogen receptors in the brain, bones, cardiovascular system, and other tissues.
Estradiol tablets are taken orally once daily. The hormone is absorbed through the GI tract and undergoes first-pass liver metabolism. This hepatic processing increases the production of certain liver proteins, including clotting factors and SHBG. The advantages are simplicity and familiarity. The clinical consideration is a modestly increased risk of venous thromboembolism compared to transdermal delivery.
Estradiol cream is applied to the skin daily. It absorbs through the dermis directly into the bloodstream, bypassing the liver. This avoids the clotting factor increase associated with oral delivery. The cream offers flexible dosing and a safe thrombotic profile. The practical trade-off is a brief daily application routine.
Estradiol patches are applied to the skin and replaced once or twice weekly. Like cream, they deliver estradiol transdermally. The unique advantage of patches is exceptionally steady hormone levels — no daily peaks and troughs. They offer the most consistent delivery, the best thrombotic safety, and the lowest maintenance routine of any systemic option.
Two of Luvo’s estradiol options deliver the hormone directly to the vaginal and urogenital tissues, with minimal absorption into the systemic circulation.
Estradiol vaginal gel is applied intravaginally using a measured applicator. It distributes across the vaginal walls and provides concentrated estrogen to the tissue that needs it most. Vaginal gel is effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms.
Estradiol vaginal tablets are small tablets inserted vaginally. They dissolve in place and release estradiol locally. The tablet format is clean, precise, and mess-free. Like the gel, it effectively treats GSM symptoms.
Both vaginal formulations produce very low systemic estradiol levels — typically remaining within the normal postmenopausal range. This makes them appropriate for women who need localized therapy but want to avoid or minimize systemic estrogen exposure.
Many women benefit from using more than one estradiol formulation simultaneously. This isn’t over-treatment — it’s targeted treatment.
The most common combination is a systemic formulation (tablets, cream, or patches) for hot flashes, mood, sleep, and bone protection, plus a vaginal formulation (gel or tablets) for concentrated urogenital symptom relief. Systemic estradiol provides some benefit to vaginal tissues, but many women find it insufficient for significant GSM symptoms. Adding vaginal estradiol provides the concentrated local effect these tissues need.
Your Luvo provider designs the combination based on your specific symptom profile. A woman whose primary complaints are hot flashes and insomnia might start with patches alone. If vaginal dryness develops later, vaginal gel or tablets can be added without changing the systemic component.
This modular approach — building and adjusting a multi-formulation protocol over time — is one of the key advantages of Luvo’s 10-medication program.
Here’s a practical summary to aid your decision.
Estradiol tablets are best for women who want simple daily dosing and have no elevated clotting risk. Application is a daily pill with no skin considerations. They offer the most straightforward routine but do carry modestly elevated thrombotic risk.
Estradiol cream is best for women wanting transdermal safety with flexible dosing. Application is daily to the skin with a brief drying period. It offers good safety and dose adjustability.
Estradiol patches are best for women wanting the steadiest levels and lowest maintenance. Application is once or twice weekly to the skin. They offer the most consistent delivery and best thrombotic safety.
Estradiol vaginal gel is best for vaginal dryness and urogenital symptoms. Application is intravaginal with an applicator. It provides excellent localized therapy with minimal systemic absorption.
Estradiol vaginal tablets are best for the same symptoms as gel with a cleaner, more precise format. Application is a small tablet inserted vaginally. It provides the same targeted relief with less mess.
Explore each option in detail: estradiol tablets, estradiol cream, estradiol patches, estradiol vaginal gel, and estradiol vaginal tablets. Or visit Luvo’s hormone replacement program for a comprehensive evaluation.
One of the biggest mistakes in women’s healthcare is treating menopause as a single event rather than a multi-year transition with distinct phases. A 44-year-old woman experiencing her first irregular periods and occasional hot flashes has very different needs than a 55-year-old woman who has been postmenopausal for four years and is dealing with vaginal atrophy and bone loss.
Yet many HRT programs — and many providers — apply the same approach regardless of stage. Luvo’s hormone replacement program is designed around the reality that different phases require different treatment strategies, and our 10-medication toolkit gives providers the flexibility to match treatment to phase.
Perimenopause typically begins in the mid-40s (though it can start in the late 30s) and lasts an average of 4–8 years. It’s defined by fluctuating and declining ovarian function, with estrogen levels that can swing wildly — sometimes higher than normal, sometimes crashing to postmenopausal levels, sometimes changing dramatically within a single cycle.
This hormonal chaos produces symptoms that can be confusing and unpredictable. Irregular periods are the hallmark — cycles may become shorter, longer, heavier, lighter, or skip entirely. Hot flashes may come and go. Sleep disruption often begins in earnest. Mood symptoms including anxiety, irritability, and depression are frequently reported — and are often the first symptoms women seek help for, sometimes without realizing the hormonal connection.
Brain fog and difficulty concentrating catch many perimenopausal women off guard. The cognitive changes can be alarming, particularly for women in demanding careers who rely on mental sharpness.
Because hormone levels during perimenopause are unpredictable rather than consistently low, treatment approaches need to be flexible and responsive.
Managing perimenopause requires accommodating hormonal variability rather than simply replacing a consistent deficit.
Low-dose estradiol in tablet, cream, or patch form can stabilize the hormonal fluctuations that drive symptoms. The goal isn’t to replace estrogen (the ovaries are still producing it, albeit irregularly) but to smooth out the peaks and valleys. Transdermal formulations may be particularly useful because they provide steady delivery that counterbalances the ovarian instability.
Non-hormonal options are sometimes the right starting point for perimenopausal women. Paroxetine or Desvenlafaxine can address the mood symptoms and hot flashes that are often the primary complaints during this phase, without introducing additional hormones into an already fluctuating system.
Testosterone may be relevant for perimenopausal women already experiencing libido decline and fatigue, though it’s more commonly introduced later. Luvo’s availability of testosterone in injection, tablet, and gel form means it can be added when the clinical picture warrants.
The key during perimenopause is regular reassessment. Symptoms and hormonal status evolve continuously, and treatment should evolve with them. Luvo’s ongoing provider relationship supports this adaptive approach.
After 12 months without a period, you’ve reached menopause. From this point forward, estrogen levels are consistently low and continue to decline gradually. The treatment approach shifts from managing fluctuations to addressing a stable, ongoing hormone deficit.
Systemic estradiol becomes more clearly indicated if you’re experiencing hot flashes, night sweats, sleep disruption, mood changes, or want the bone and cardiovascular protection that estrogen provides within the window of opportunity. Your Luvo provider will recommend tablets, cream, or patches based on your risk profile and preferences.
Vaginal estradiol often becomes increasingly important as GSM symptoms develop or worsen in postmenopause. Many women need both systemic and localized therapy to address the full spectrum of symptoms. Luvo’s vaginal gel and vaginal tablets provide targeted relief for urogenital concerns.
Testosterone therapy becomes more relevant as the combined effect of ovarian and adrenal testosterone decline becomes clinically significant. Many postmenopausal women who’ve been on estradiol-only HRT experience a dramatic quality-of-life improvement when testosterone is added.
Non-hormonal options remain available for women entering postmenopause who have contraindications to estrogen or who have found Paroxetine or Desvenlafaxine effective during perimenopause and wish to continue.
The transition from perimenopause through menopause and into postmenopause is a years-long journey, and your treatment needs will change along the way. A protocol that works at 46 may need significant revision by 52.
Luvo’s program is designed for this reality. Our providers don’t just prescribe a treatment and move on — they partner with you through the entire transition, adjusting medications, doses, and delivery methods as your body and symptoms evolve.
With 10 medications available, there’s always room to optimize. Starting with a non-hormonal approach and adding estradiol when appropriate. Switching from oral to transdermal if risk factors emerge. Adding vaginal estradiol as GSM develops. Incorporating testosterone when libido and energy become priorities. The flexibility is the point.
Visit Luvo’s hormone replacement program to begin your evaluation, or explore our options: estradiol tablets, cream, patches, vaginal gel, vaginal tablets, testosterone injection, tablets, gel, Paroxetine, and Desvenlafaxine.
If your understanding of hormone replacement therapy is shaped by headlines from 20 years ago, it’s time for an update. The 2002 Women’s Health Initiative (WHI) study sent shockwaves through medicine, leading millions of women to abandon HRT and a generation of physicians to stop prescribing it. But the decades since have brought dramatic clarity: the WHI’s findings were widely misinterpreted, and the resulting fear of HRT caused immeasurable harm to women who could have benefited from treatment.
Today, major medical organizations including the North American Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists affirm that HRT is safe and effective for most women experiencing menopause symptoms, particularly when started within 10 years of menopause onset.
Luvo’s hormone replacement program is built on this modern evidence base. With 10 medication options spanning estradiol formulations, testosterone therapy, and non-hormonal alternatives, it offers a level of treatment personalization that most competitors simply can’t match.
Menopause isn’t a single event — it’s a transition that typically spans several years. The process begins in perimenopause, usually in the mid-40s, when the ovaries begin producing less estrogen and progesterone. Hormone levels fluctuate unpredictably, causing symptoms that can range from mildly annoying to severely disruptive.
Menopause is officially reached when 12 consecutive months pass without a menstrual period, typically around age 51. At this point, the ovaries have largely ceased producing estrogen, and levels of this hormone remain permanently low.
Estrogen isn’t just a reproductive hormone. It has receptors throughout the body — in the brain, bones, cardiovascular system, urogenital tract, skin, and joints. When estrogen declines, the effects cascade across multiple systems: vasomotor symptoms like hot flashes and night sweats, sleep disruption, mood changes and cognitive fog, vaginal dryness and urogenital atrophy, bone density loss, cardiovascular risk changes, joint pain and muscle loss, and skin and hair changes.
Testosterone also declines in women, though more gradually. By menopause, a woman’s testosterone level may be half what it was in her 20s, contributing to decreased libido, reduced energy, and loss of muscle mass.
HRT addresses these declines by restoring hormones to levels that alleviate symptoms and protect long-term health.
What sets Luvo apart from competitors like Hims, Willow, or Pomegranate is the breadth of our medication options. Managing hormonal decline isn’t one-size-fits-all, and neither is our program.
Estradiol is available in five formulations: oral tablets for systemic hormone delivery, transdermal cream for absorption through the skin, transdermal patches for steady-state hormone levels, vaginal gel for localized urogenital symptom relief, and vaginal tablets for targeted vaginal atrophy treatment.
Testosterone for women is available in three formulations: injection, oral tablets, and topical gel — addressing the often-overlooked role of testosterone in female vitality, libido, and body composition.
Non-hormonal options include Paroxetine, the only FDA-approved non-hormonal treatment for vasomotor symptoms, and Desvenlafaxine, an SNRI with strong evidence for hot flash reduction. These serve women who cannot or prefer not to use hormonal therapy.
This 10-medication toolkit means your Luvo provider can design a protocol precisely matched to your symptoms, health history, preferences, and risk profile.
HRT is most clearly indicated for women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats, women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular and bone benefits), women with premature ovarian insufficiency or early menopause (before age 40), women with significant urogenital symptoms like vaginal dryness, painful intercourse, or recurrent UTIs, and women at elevated risk for osteoporosis.
HRT may require additional evaluation or alternatives for women with a history of breast cancer, women with active cardiovascular disease or a history of blood clots, women with undiagnosed vaginal bleeding, and women with active liver disease.
Luvo’s providers conduct thorough health evaluations to determine the safest and most effective approach for each patient. For women who cannot use estrogen, our non-hormonal options provide meaningful symptom relief.
Explore Luvo’s full hormone replacement program to learn more.